Physician profile
Mitchell F Mayer
NPI 1639173008
$7,645.99
in general payments reported to CMS, 2019-2025
44 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $925 · 2021: $192 · 2022: $857 · 2023: $1,045 · 2024: $1,543 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,053.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $952.81 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $851.69 | 2019-2025 | |
| Novo Nordisk INC | $826.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $658.82 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $578.65 | 2023-2025 | |
| Exact Sciences Corporation | $486.13 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $406.72 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $335.24 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $306.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.85 | 2019-2025 | Jardiance, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $242.43 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $146.09 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $141.42 | 2019-2020 | |
| Abbott Laboratories | $127.91 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $125.26 | 2022-2025 | Dexcom G6 Transmitter |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.